Aclaris Therapeutics, Inc. SEC filings ACRS
Aclaris Therapeutics, Inc. has 872 filings in SEC EDGAR's recent list, going back to Sep 10, 2012. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 7, 2025 | — |
| CORRESP | Letter to the SEC | Mar 5, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2025 | — |
| EFFECT | Filing | Dec 31, 2024 | — |
| CORRESP | Letter to the SEC | Dec 27, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2024 | — |
| D | Filing | Dec 4, 2024 | — |
| EFFECT | Filing | Apr 29, 2020 | — |
| CORRESP | Letter to the SEC | Apr 23, 2020 | — |
| D | Filing | Apr 8, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2020 | — |
| CT ORDER | Filing | May 9, 2019 | — |
| CT ORDER | Filing | Dec 20, 2018 | — |
| CT ORDER | Filing | Sep 4, 2018 | — |
| D/A | Filing | Aug 13, 2018 | — |
| CT ORDER | Filing | May 17, 2018 | — |
| CT ORDER | Filing | Nov 14, 2017 | — |
| D | Filing | Aug 14, 2017 | — |
| EFFECT | Filing | Dec 1, 2016 | — |
| EFFECT | Filing | Nov 14, 2016 | — |
| CORRESP | Letter to the SEC | Nov 10, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2016 | — |
| EFFECT | Filing | Jun 28, 2016 | — |
| CORRESP | Letter to the SEC | Jun 24, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2016 | — |
| CT ORDER | Filing | Jun 23, 2016 | — |
| D | Filing | Jun 14, 2016 | — |
| CT ORDER | Filing | Dec 1, 2015 | — |
| EFFECT | Filing | Oct 6, 2015 | — |
| CERTNAS | Auto-generated paper document | Oct 6, 2015 | — |
| 8-A12B | Filing | Oct 2, 2015 | — |
| CORRESP | Letter to the SEC | Oct 2, 2015 | — |
| CORRESP | Letter to the SEC | Oct 2, 2015 | — |
| D | Filing | Sep 11, 2015 | — |
| CORRESP | Letter to the SEC | Sep 3, 2015 | — |
| CORRESP | Letter to the SEC | Aug 17, 2015 | — |
| UPLOAD | Letter from the SEC | May 26, 2015 | — |
| DRS/A | Filing | May 14, 2015 | — |
| DRSLTR | Filing | May 13, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2015 | — |
| DRS | Filing | Apr 2, 2015 | — |
| D | Filing | Oct 8, 2014 | — |
| D | Filing | Sep 10, 2012 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557746
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.